Non-invasive methods for the diagnosis of ulcerative colitis
https://doi.org/10.31146/1682-8658-ecg-180-8-114-121
Abstract
In recent years, with the improvement of laboratory diagnostics, fundamentally new serum and fecal markers have ap-peared that allow increasing the accuracy of the diagnosis of ulcerative colitis, assessing the degree of disease activity, the effectiveness of treatment, and screening for colorectal cancer. The article presents current data on genetic, fecal, and serum markers that may be included in modern valuable diagnostic panels for the diagnosis of ulcerative colitis in the future.
About the Authors
G. R. Bikbavova
Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Bikbavova Galiya Ravilievna - candidate of medical sciences, associate professor of the Department of Hospital Therapy, Endocrinology.
St. Lenina, 12, Omsk, 644099
V. A. Akhmedov
Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Vadim A. Akhmedov - MD, professor, head of the department of medical rehabilitation of additional professional education.
St. Lenina, 12, Omsk, 644099
D. G. Novikov
Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Novikov Dmitry Georgievich - candidate of medical sciences, associate professor of the Department of Clinical Laboratory Diagnostics of Continuing Professional Education.
St. Lenina, 12, Omsk, 644099
A. N. Podsokhin
Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Podsokhin Aleksey Nikolaevich - resident of the Department of Hospital Therapy, Endocrinology.
St. Lenina, 12, Omsk, 644099
S. N. Podsokhin
Omsk State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Podsokhin Sergey Nikolaevich - resident of the Department of Hospital Therapy, Endocrinology.
St. Lenina, 12, Omsk, 644099
References
1. Christodoulou K, Wiskin AE, Gibson J. et al. Next gen-eration exome sequencing of paediatric infl ammatory bowel disease patients identifi es rare and novel variants in candidate genes. Gut, 2013, Vol. 62, no. 7, pp. 977–984. doi: 10.1136/gutjnl-2011–301833.
2. Soubières AA, Poullis A. Emerging biomarkers for the di-agnosis and monitoring of infl ammatory bowel diseases.
3. Infl amm Bowel Dis, 2016, vol. 22, no. 8, pp. 2016–2022. doi: 10.1097/MIB.0000000000000836
4. Cheon JH. Genetics of infl ammatory bowel diseases: a comparison between Western and Eastern perspectives.
5. J Gastroenterol Hepatol, 2013, vol. 28, no. 2, Pp. 220–226. doi: 10.1111/jgh.12053.
6. Bin C., Zhirong Z., Xiaoqin W. et al. Contribution of rs11465788 in IL23R gene to Crohn’s disease suscepti-bility and phenotype in Chinese population. J Genet, 2009, vol. 88, no. 2, pp191–196. DOI: 10.1007/s12041–009–0027–9
7. Jürgens M., Laubender R. P., Hartl F. et al. Disease activity, ANCA, and IL23R genotype status determine early response to infl iximab in patients with ulcerative colitis. Am J Gastroenterol, 2010, vol. 105, no. 8 pp. 1811–1919. doi: 10.1038/ajg.2010.95.
8. Rump J. A., Schölmerich J., Gross V. et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s disease. Immunobiology, 1990, vol. 181, no 4–5, pp. 406– 413. DOI: 10.1016/S0171–2985(11)80509–7
9. Vidrich A., Lee J., James E. et al. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis, J Clin Immunol, 1995, vol. 15, no. 6, pp. 293–299. DOI: 10.1007/BF01541319
10. Lodes M. J., Cong Y., Elson C. O. et al. Bacterial fl agellin is a dominant antigen in Crohn disease, J Clin Invest. 2004, vol. 113, no. 9, pp. 1296–1306. DOI: 10.1172/JCI20295
11. Dotan I., Fishman S., Dgani Y. et al. Antibodies against laminaribioside and chitobioside are novel sero-logic markers in Crohn’s disease, Gastroenterology. 2006, vol.131, no. 2, pp:366–378. DOI: 10.1053/j.gas-tro.2006.04.030
12. Ghosh S., Goldin E., Gordon F. H. et al. Natalizumab for active Crohn’s disease. N Engl J Med, 2003, vol. 348, no. 1, pp. 24–32. DOI: 10.1056/NEJMoa020732
13. Sendid B., Colombel J. F., Jacquinot P. M. et al. Specifi c antibody response to oligomannosidic epitopes in Crohn’s disease. Clinical and Diagnostic Laboratory Immunology, 1996, vol.3, no, 2, pp. 219–226.
14. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus.
15. Th e Journal of Experimental Medicine, 1930, vol.52, no. 4, Pp. 561–571. DOI: 10.1084/jem.52.4.561
16. Abdelrazeq A. S., Wilson T. R., Leitch D. L. et al. Ileitis in ulcerative colitis: is it a backwash? Diseases of the Colon and Rectum, 2005, vol, 48, no. 11, pp. 2038–2046. DOI: 10.1007/s10350–005–0160–3
17. Okba A. M., Amin M. M., Abdelmoaty A. S. et al. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. Autoimmun Highlights, 2019, vol 10, no. 1, pp. 4. doi: 10.1186/s13317–019–0114–8.
18. Fagerhol M, K,, Dale I,, Andersson T. A radioimmu-noassay for a granulocyte protein as a marker in stud-ies on the turnover of such cells. Bulletin Europeen de Physiopathologie Respiratoire, 1980, vol 16, supple-ment, pp. 273–282. DOI: 10.1016/b978–0–08–027379–2.50028–4
19. Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult infl ammatory bowel disease. World Journal of Gastroenterology, 2012, vol.18, no. 46, pp. 6782–6789. doi: 10.3748/wjg.v18.i46.6782.
20. Schoepfer A.M, Trummler M., Seeholzer P. et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Infl ammatory Bowel Diseases, 2008, vol. 14, no. 1, pp. 32–39. DOI: 10.1002/ibd.20275
21. von Roon A. C., Karamountzos L., Purkayastha S. et al. Diagnostic precision of fecal calprotectin for infl am-matory bowel disease and colorectal malignancy. Th e American Journal of Gastroenterology, 2007, vol. 102, no. 4, pp. 803–813. DOI: 10.1111/j.1572–0241.2007.01126.x
22. Ricanek P., Brackmann S., Perminow G. et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scandinavian Journal of Gastroenterology, 2011, vol. 46, no. 9, pp. 1081–1091. DOI: 10.3109/00365521.2011.584897
23. Sipponen T., Savilahti E., Kärkkäinen P. et al. Fecal cal-protectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s dis-ease. Infl ammatory Bowel Diseases, 2008, vol.14, no.10, pp.1392–1398. doi: 10.1002/ibd.20490.
24. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with infl ammatory bowel disease. Scandinavian Journal of Gastroenterology, 2004, vol.39, no.10, pp. 1017–1020. DOI: 10.1080/00365520410007971
25. Mao R., Xiao Y. L., Gao X. et al. Fecal calprotectin in predicting relapse of, infl ammatory bowel diseases: a meta-analysis of prospective studies. Inflammatory Bowel Diseases, 2012, vol.18, no. 10, pp.1894–1899. doi: 10.1002/ibd.22861.
26. Baveye S., Elass E., Mazurier J. et al. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the infl ammatory process. Clinical Chemistry and Laboratory Medicine, 1999, vol.37, no. 3, pp. 281–286. DOI: 10.1515/CCLM.1999.049
27. Joishy M, Davies I, Ahmed Ml. Fecal calprotectin and lac-toferrin as noninvasive markers of pediatric infl ammato-ry bowel disease. Journal of Pediatric Gastroenterology and Nutrition, 2009, vol. 48, no. 1, pp. 48–54. doi: 10.1097/MPG.0b013e31816533d3.
28. Sugi K., Saitoh O., Hirata I. et al. Fecal lactoferrin as a marker for disease activity in infl ammatory bowel disease: comparison with other neutrophil-derived pro-teins. Th e American Journal of Gastroenterology, 1996, vol. 91, no.5, pp. 927–934.
29. Kane SV, Sandborn WJ, Rufo P. A. et al. Fecal lactoferrin is a sensitive and specifi c marker in identifying intestinal inflammation. The American Journal of Gastroenterology, 2003, vol. 98, no. 6, pp. 1309–1314. DOI: 10.1111/j.1572–0241.2003.07458.x
30. Nancey S., Boschetti G., Moussata D. et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with infl ammatory bowel diseases. Infl ammatory Bowel Diseases. 2013, vol. 19, no. 5, pp. 1043–1052. doi: 10.1097/MIB.0b013e3182807577.
31. Husain N., Tokoro K., Popov J. M. et al. Neopterin con-centration as an index of disease activity in Crohn’s disease and ulcerative colitis. Journal of Clinical Gastroenterology, 2013, vol. 47, no. 3, pp. 246–251. doi: 10.1097/MCG.0b013e3182582cdb.
32. van de Logt F, Day AS. S100A12: a noninvasive marker of infl ammation in infl ammatory bowel disease. Journal of Digestive Diseases, 2013, vol. 14, no. 2, pp. 62–67. doi: 10.1111/1751–2980.12012.
33. Turner D., Leach S. T., Mack D. Faecal calprotectin, lac-toferrin, M2-pyruvate kinase and S100A12 in severe ul-cerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010, vol. 59, no. 9, pp. 1207–1212. doi: 10.1136/gut.2010.211755.
34. Kaiser T., Langhorst J., Wittkowski H. et al. Faecal S100A12 as a non-invasive marker distinguishing infl ammatory bowel disease from irritable bowel syndrome. Gut, 2007, vol. 56, no. 12, pp. 1706–1713. DOI: 10.1136/gut.2006.113431
35. Foell D., Kucharzik T., Kraft M. et al. Neutrophil de-rived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut, 2003, vol. 52, no. 6, pp. 847–853. DOI: 10.1136/gut.52.6.847
36. O’Connell R.M., Rao D. S., Chaudhuri A. A. et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol., 2010, vol. 10, no.
37. Dalal S.R, Kwon J. H. Th e role of MicroRNA in infl am-matory bowel disease. Gastroenterol Hepatol, 2010, vol. 6, no. 11, pp. 714–722.
38. Wu F., Zhang S., Dassopoulos T. et al. Identifi cation of microRNAs associated with ileal and colonic Crohn’s disease. Infl amm Bowel Dis, 2010, vol.16, no. 10, pp. 1729–1738. doi: 10.1002/ibd.21267.
39. Iborra M., Bernuzzi F., Correale C. et al. Identifi cation of serum and tissue micro-RNA expression profi les in different stages of infl ammatory bowel disease. Clin Exp Immunol, 2013, vol.173, no.2, pp. 250–258. doi: 10.1111/cei.12104.
40. De Iudicibus S., Lucafò M., Martelossi S. et al. MicroRNAs as tools to predict glucocorticoid response in infl amma-tory bowel diseases. World J Gastroenterol, 2013, vol. 19, no. 44 pp. 7947–7954. doi: 10.3748/wjg.v19.i44.7947.
41. Fujioka S., Nakamichi I., Esaki M. et al. Serum microRNA levels in patients with Crohn’s disease during induction therapy by infl iximab. J Gastroenterol Hepatol, 2014, vol. 29, No. 6, pp. 1207–1214. doi: 10.1111/jgh.12523.
42. Judmaier G., Meyersbach P., Weiss G. et al. Th e r ole o f neopterin in assessing disease activity in Crohn’s disease: classifi cation and regression trees. Th e American Journal of Gastroenterology, 1993, vol. 88, no. 5, pp 706–711.
43. Prior C., Bollbach R, Fuchs D. et al. Urinary neopterin, a marker of clinical activity in patients with Crohn’s disease. Clinica Chimica Acta, 1986, vol.155, no. 1. Pp. 11–21. DOI: 10.1016/0009–8981(86)90094-x
44. Nancey S, Perret-Liaudet A, Moussata D. et al. Urinary neopterin is a valuable tool in monitoring Crohn’s dis-ease activity. Infl ammatory Bowel Diseases. 2008, vol. 14, no.11, pp. 1548–1554. doi: 10.1002/ibd.20510.
45. Niederwieser D., Fuchs D., Hausen A. Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology, 1985, vol.170, no. 4, pp. 320–326. DOI: 10.1016/S0171–2985(85)80080–2
46. Li H, Tago K, Io K. et al. Th e cloning and nucleotide sequence of human ST2L cDNA. Genomics, 2000, vol.67, no. 3, pp. 284–290. DOI: 10.1006/geno.2000.6269
47. Diaz-Jimenez D., Nunez L. E., Beltran C. J. Soluble ST2: a new and promising activity marker in ulcerative colitis. World Journal of Gastroenterology. 2011, vol. 17, no. 17, pp. 2181–2190. doi: 10.3748/wjg.v17.i17.2181.
48. Tavano F., di Mola F. F., Latiano A. et al. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. Journal of Crohn’s and Colitis, 2012, vol. 6, no. 5, pp. 563–570. doi: 10.1016/j.crohns.2011.11.004.
49. Nakarai A., Kato J., Hiraoka S. Evaluation of muco-sal healing of ulcerative colitis by a quantitative fe-cal immunochemical test. Th e American Journal of Gastroenterology, 2013, vol.108, no. 1, pp. 83–89. doi: 10.1038/ajg.2012.315
50. Aomatsu T., Imaeda H., Matsumoto K. et al. Faecal chiti-nase 3-like-1: a novel biomarker of disease activity in paediatric infl ammatory bowel disease. Alimentary Pharmacology and Th erapeutics, 2011, vol. 34, no. 8, pp. 941–948. doi: 10.1111/j.1365–2036.2011.04805.x
51. Battat R., Dulai P. S., Vande Casteele N. et al. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
52. Infl amm Bowel Dis, 2019, vol. 25, no. 2, pp. 410–420. doi: 10.1093/ibd/izy307. 49. Ticho A. L., Malhotra P., Dudeja P. K. et al. Intestinal Absorption of Bile Acids in Health and Disease. Compr Physiol, 2019, vol. 10, no. 1, pp. 21–56. doi: 10.1002/cphy.c190007.
53. Stojancevic M., Stankov K., Mikov M. Th e impact of farne-soid X receptor activation on intestinal permeability in infl ammatory bowel disease. Can. J. Gastroenterol. 2012, vol. 26, no. 9, pp. 631–637. DOI: 10.1155/2012/538452
54. Czub E., Herzig K. H., Szafl arska-Popławska A. et al. Fecal pyruvate kinase: a potential new marker for intestinal in-fl ammation in children with infl ammatory bowel disease.
55. Scandinavian Journal of Gastroenterology, 2007, vol. 42, no. 10, pp. 1147–1150. DOI: 10.1080/00365520701320513
56. Walkowiak J., Banasiewicz T., Krokowicz P. et al. Fecal pyruvate kinase (M2-PK): a new predictor for infl am-mation and severity of pouchitis. Scandinavian Journal of Gastroenterology, 2005, vol.40, no. 12, pp. 1493–1494. DOI: 10.1080/00365520500319112
57. McDowell G., Gupta S., Dellerba M. et al. Plasma con-centrations of tumour dimeric pyruvate kinase are increased in patients with chronic failure. Annals of Clinical Biochemistry, 2004, vol.41, no. 6, pp. 491–493. DOI: 10.1258/0004563042466712
58. Oehler R., Weingartmann G., Manhart N., et al. Polytrauma induces increased expression of pyruvate kinase in neutro-phils. Blood, 2000, vol.95, no. 3, pp. 1086–1092.
59. Chung-Faye G., Hayee B., Maestranzi S. et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal infl ammation. Infl ammatory Bowel Diseases, 2007, vol. 13, no. 11, pp. 1374–1378. DOI: 10.1002/ibd.20214
60. Fasseu M., Tréton X., Guichard C. et al. Identifi cation of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with infl ammatory bowel disease. PLoS ONE, 2010, vol. 5, no. 10, e13160. doi: 10.1371/journal.pone.0013160.
61. Wu C. W., Ng S. S., Dong Y. J. et al. Detection of miR-92a and miR-21 in stool samples as potential screening bio-markers for colorectal cancer and polyps. Gut, 2012, vol. 61, No. 5, pp. 739–745. doi: 10.1136/gut.2011.239236.
62. Chen C. C., Pekow J., Llado V. et al. Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia. Th e A merican Journal of Pathology, 2011, vol. 179, no. 3, pp. 1494–1503. doi: 10.1016/j.ajpath.2011.05.038.
63. Fonseca-Camarillo G., Yamamoto-Furusho J. K. Immunoregulatory pathways involved in infl ammato-ry bowel disease. Infl amm Bowel Dis, 2015, vol.21, no. 9, pp. 2188–2129. doi: 10.1097/MIB.0000000000000477.
64. Parronchi P., Romagnani P., Annunziato F. et al. Type 1 T-helper cell predominance and interleukin-12 expres-sion in the gut of patients with Crohn’s disease. Am J Pathol, 1997, vol.150, no. 3, pp. 823–832.
65. León A. J., Gómez E., Garrote J. A. et al. High levels of proinfl ammatory cytokines, but not markers of tissue injury, in unaff ected intestinal areas from patients with IBD. Mediators Infl amm, 2009, vol.2009 pp. 580450. doi: 10.1155/2009/580450.
66. Andoh A., Shioya M., Nishida A. et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in infl ammatory bowel disease. J Immunol, 2009, vol.183, no. 1, pp. 687–695. doi: 10.4049/jimmu-nol.0804169.
67. Camarillo G. F., Furuzawa-Carballeda J., Martínez-Benítez B. et al. Role of the interleukin 24 in patients with ulcerative colitis. Infl amm Bowel Dis, 2011, vol.17, no. 10, pp. 2209–2210. doi: 10.1002/ibd.21635.
Review
For citations:
Bikbavova G.R., Akhmedov V.A., Novikov D.G., Podsokhin A.N., Podsokhin S.N. Non-invasive methods for the diagnosis of ulcerative colitis. Experimental and Clinical Gastroenterology. 2020;(8):114-121. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-180-8-114-121
Views:
342
Email this article 